Вибекотамаб

Rec. INN (наименование, зарегистрированное ВОЗ)

USAN (наименование, принятое к употреблению в США)

2138442-13-2

immunoglobulin half-G1-kappa/scFv-h-CH2-CH3, anti- [Homo sapiens IL3RA (interleukin 3 receptor subunit alpha, interleukin 3 receptor, alpha (low affinity), CD123) and Homo sapiens CD3 epsilon (CD3E, Leu-4)], monoclonal antibody, bispecific;
gamma1 heavy chain anti-IL3RA (1-449) [VH (Mus musculus IGHV1-26*01(83.7%) -(IGHD) -IGHJ3*01(93.3%)/Homo sapiens IGHV1-46*01 (78.6%) -(IGHD) -IGHJ6*01 (90.9%)) [8.8.13] (1-120) -Homo sapiens IGHG1*03v (CH1 N114>D (211), R120>K (217) (121-218), hinge 1-15 (219-233), CH2 E1.4>P (236), L1.2>V (237), G1.1>A (238), S29>K (269), Q84.2>E (297) (234-342), CH3 E12 (358), M14 (360), L24>D (370), K26>S (372), N44>D (386), Q97>E (420), N100>D (423) (343- 447), CHS (448-449)) (121-449)], (223- 220')-disulfide with kappa light chain anti IL3RA (1'-220') [VKAPPA (Homo sapiens IGKV4-1*01 (89.1%) -IGKJ2*01 (91.7%)) [12.3.9] (1'-113') -Homo sapiens IGKC*01 (100%) A45.1 (159), V101 (197) (114'-220')];
heavy chain scFv-h-CH2-CH3, anti-CD3E (1-485) [VH (Homo sapiens IGHV3-73*01 (87.0%) -(IGHD) -IGHJ6*01 (90.9%)) [8.10.16] (1-125) -20-mer linker (126-145) -VLAMBDA (Mus musculus IGLV1*01 (80.6%) -IGLJ1*01 (100%)/Homo sapiens IGLV7-46*01 (76.8%) -IGHJ3*02 (100%)) [9.3.9] (146-254) -IGHG1*03 (hinge 1-15 C5>S (259) (255-269) -CH2 E1.4>P (272), L1.2>V (273), G1.1>A (274), S29>K (305) (270-378),CH3 E12 (394), E13>Q (395), M14 (396), S20>K (402)(379-483), CHS (484-485)) (1-485)]; dimer (229-265'':232-268'')-bisdisulfide

Поделиться этой страницей